SAGE — Sage Therapeutics Share News
0.000.00%
Last trade - 00:00- $544.97m
- $121.11m
- $41.24m
Brief: Sage Announces Results From Phase 2 Study Of Dalzanemdor In Treatment Of Mild Cognitive Impairment And Mild Dementia In Alzheimer’s Disease
Sage Therapeutics to discontinue development of Alzheimer’s drug
Sage Therapeutics falls after Biogen terminates tremor drug partnership
Brief: SAGE Therapeutics Announces Discontinuation Of The Collaboration With Biogen On The Sage-324 Program
Advisory: Incorrect research alert on Sage Therapeutics Inc withdrawn
U.S. RESEARCH ROUNDUP-CH Robinson Worldwide, Lam Research, Meta
Sage Therapeutics Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: SAGE Therapeutics Q2 Product Revenue USD 600 Thousand
Sage Therapeutics Inc Expected To Post A Loss Of $1.66 A Share: Earnings Preview
U.S. RESEARCH ROUNDUP-Edwards Lifesciences, National Bank Holdings, Sage Therapeutics
U.S. STOCKS ON THE MOVE-Tesla, Lamb Weston, Blackstone Mortgage Trust
U.S. STOCKS ON THE MOVE-FTAI Aviation, Check Point, Sage Therapeutics
Sage shares decline on plans to scrap development of tremor drug
Sage shares decline on plans to scrap development of tremor drug
Biogen and Sage to scrap neurological disorder drug development after trial failure (updated)
Brief: Sage Therapeutics And Biogen Announce Topline Results From Phase 2 Kinetic 2 Study Of SAGE-324 (BIIB124) For The Treatment Of Essential Tremor
Biogen and Sage's neurological disorder drug fails in mid-stage trial
U.S. RESEARCH ROUNDUP: Boston Beer Company, Inter Parfums, Netflix
U.S. RESEARCH ROUNDUP-Nvidia, Qualcomm, Tesla